NPC Archive Item: Lower HbA1c associated with increased risk of car crashes in people with diabetes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 January 2010 A Canadian case-control study has found an association between low HbA1c and risk of car crashes in people with diabetes. They found a relative increase in […]

NPC Archive Item: Observational study of hypoglycaemic drugs has limitations

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15th January 2010 Compared with metformin monotherapy, the fully adjusted analysis in this UK cohort study found no increased risk of heart failure or myocardial infarction with pioglitazone▼ or […]

NPC Archive Item: Study of insulin detemir should not deflect from NICE guidance

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 30 November 2009 This open label randomised trial suggests that using insulin detemir in people with type 2 diabetes leads to similar median HbA1c levels as twice daily biphasic […]

NPC Archive Item: Intensive blood glucose control in type 1 diabetes reduces complications long-term

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2nd September 2009 Observational follow-up of two cohorts of people with type 1 diabetes over 30 years has found that the cumulative incidences of some serious complications are lower […]

NPC Archive Item: More on glitazone safety: how do pioglitazone▼ and rosiglitazone compare?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2nd September 2009 Two recently published Canadian cohort studies have assessed cardiovascular safety and fracture risk with pioglitazone▼ and rosiglitazone. The BMJ study found pioglitazone▼ was associated with a […]

NPC Archive Item: Intensive glucose control in type 2 diabetes: conclusions unchanged

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 3rd August 2009 A meta-analysis of prospective randomised controlled trials suggests a small benefit of intensive glucose control in people with type 2 diabetes in reducing the risk of […]

NPC Archive Item: Latest data on saxagliptin

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 27th July 2009, A phase III, 24 week randomised controlled trial has assessed the efficacy and short-term safety of saxagliptin 2.5, 5 and 10mg versus placebo as add-on therapy […]

NPC Archive Item: Early revascularisation offers little over intensive medical therapy in type 2 diabetes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21st July 2009 This large trial found no benefit in rates of survival or major vascular events from early versus later revascularisation in people with type 2 diabetes and […]

NPC Archive Item: Insulin glargine and possible cancer link

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 9th July 2009 New data show that insulin glargine is not associated with an increase in cancer (07/08/12) Since these materials were published, ORIGIN (2012), a 6-year randomised controlled […]

NPC Archive Item: Does the LEAD-6 trial clarify the role of liraglutide▼ vs. exenatide▼ in type 2 diabetes?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 24th June 2009, updated 16th July 2009 (action and what is the background to this) The open-label LEAD-6 study compared once daily liraglutide▼ to twice daily exenatide▼ in 264 […]